Drug Trial Radar · NCT05240612
A Clinical Pharmacological Study of MT-3921 in Subjects With HTLV-1 Associated Myelopathy (HAM)
Last checked: Nov 20, 2026Latest source record: Jan 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
15
Actual
Start
May 2, 2022
Primary completion
Sep 14, 2023
Study completion Dec 28, 2023
Sponsor
- Lead sponsor
- Tanabe Pharma CorporationIndustry
- Sponsor type
- Industry
- First posted
- Feb 15, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purposes of this study is to assess the safety, tolerability, and pharmacokinetics of MT-3921 in subjects with Human T-cell Leukemia Virus Type 1 (HTLV-1)-Associated Myelopathy(HAM). Subjects meeting eligibility criteria will enter the 6-month double-blind period. Subjects will be randomized in a 2:1 ratio to receive MT-3921 or placebo in a double blind manner.
Conditions
- HTLV-1-Associated Myelopathy (HAM)
Interventions
MT-3921Biological
Solution for infusion; Intravenous (IV)
PlaceboBiological
Solution for infusion; Intravenous (IV)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of subjects with adverse eventsTime frame: 36 weeks
- Percentage of subjects with adverse reactionsTime frame: 36 weeks
- Serum concentrations of MT-3921Time frame: PK samples will be collected at predose, 1.5 hours, 2, 4, 8, 12, 20 (predose and 1.5 hours), 24, 36 weeks post-dose.
- CSF concentrations of MT-3921Time frame: PK samples will be collected at 2, 4, 12, 24 weeks post-dose.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
St. Marianna University Hospital
Kawasaki-shi, Kanagawa, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.